Houssami Nehmat, Ciatto Stefano, Macaskill Petra, Lord Sarah J, Warren Ruth M, Dixon J Michael, Irwig Les
Screening and Test Evaluation Program, School of Public Health, University of Sydney, Sydney, Australia.
J Clin Oncol. 2008 Jul 1;26(19):3248-58. doi: 10.1200/JCO.2007.15.2108. Epub 2008 May 12.
PURPOSE We review the evidence on magnetic resonance imaging (MRI) in staging the affected breast to determine its accuracy and impact on treatment. METHODS Systematic review and meta-analysis of the accuracy of MRI in detection of multifocal (MF) and/or multicentric (MC) cancer not identified on conventional imaging. We estimated summary receiver operating characteristic curves, positive predictive value (PPV), true-positive (TP) to false positive (FP) ratio, and examined their variability according to quality criteria. Pooled estimates of the proportion of women whose surgery was altered were calculated. Results Data from 19 studies showed MRI detects additional disease in 16% of women with breast cancer (N = 2,610). MRI incremental accuracy differed according to the reference standard (RS; P = .016) decreasing from 99% to 86% as the quality of the RS increased. Summary PPV was 66% (95% CI, 52% to 77%) and TP:FP ratio was 1.91 (95% CI, 1.09 to 3.34). Conversion from wide local excision (WLE) to mastectomy was 8.1% (95% CI, 5.9 to 11.3), from WLE to more extensive surgery was 11.3% in MF/MC disease (95% CI, 6.8 to 18.3). Due to MRI-detected lesions (in women who did not have additional malignancy on histology) conversion from WLE to mastectomy was 1.1% (95% CI, 0.3 to 3.6) and from WLE to more extensive surgery was 5.5% (95% CI, 3.1 to 9.5). CONCLUSION MRI staging causes more extensive breast surgery in an important proportion of women by identifying additional cancer, however there is a need to reduce FP MRI detection. Randomized trials are needed to determine the clinical value of detecting additional disease which changes surgical treatment in women with apparently localized breast cancer.
我们回顾了关于磁共振成像(MRI)在对患侧乳房进行分期以确定其准确性及对治疗影响方面的证据。方法:对MRI在检测传统成像未发现的多灶性(MF)和/或多中心性(MC)癌症方面的准确性进行系统评价和荟萃分析。我们估计了汇总的受试者工作特征曲线、阳性预测值(PPV)、真阳性(TP)与假阳性(FP)比率,并根据质量标准检查了它们的变异性。计算了手术方式改变的女性比例的合并估计值。结果:19项研究的数据显示,MRI在16%的乳腺癌女性(N = 2610)中检测到了额外的疾病。MRI的增量准确性因参考标准(RS)而异(P = 0.016),随着RS质量的提高,从99%降至86%。汇总PPV为66%(95%CI,52%至77%),TP:FP比率为1.91(95%CI,1.09至3.34)。从广泛局部切除(WLE)转为乳房切除术的比例为8.1%(95%CI,5.9至11.3),在MF/MC疾病中从WLE转为更广泛手术的比例为11.3%(95%CI,6.8至18.3)。由于MRI检测到的病变(在组织学上没有额外恶性肿瘤的女性中),从WLE转为乳房切除术的比例为1.1%(95%CI,0.3至3.6),从WLE转为更广泛手术的比例为5.5%(95%CI,3.1至9.5)。结论:MRI分期通过识别额外的癌症,在相当比例的女性中导致更广泛的乳房手术,然而有必要减少MRI检测中的假阳性。需要进行随机试验来确定检测到改变明显局限性乳腺癌女性手术治疗的额外疾病的临床价值。